Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule

Author:

Totterdell James A.ORCID,Chacon Gladymar Perez,Estcourt Marie J.,Jones Mark,Richmond Peter,Snelling Thomas L.,Marsh Julie A.

Abstract

AbstractObjectiveThe purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule.ParticipantsUp to 3000 Australian infants 6 to <12 weeks of age born ≥32 weeks gestation.InterventionsThe intervention is a wP containing vaccine as the first scheduled pertussis vaccine dose instead of an aP containing vaccine.OutcomesThe primary outcome is a binary indicator of history of IgE-mediated food allergy at the age of 12 months confirmed, where necessary, with an oral food challenge before 18 months of age. Secondary outcomes include (1) history of parent-reported clinician-diagnosed new onset of atopic dermatitis by 6 or 12 months of age with a positive skin prick test to any allergen before 12 months of age, (2) geometric mean concentration in pertussis toxin-specific IgG before and 21 to 35 days after a booster dose of aP at 18 months of age, and (3) sensitisation to at least one allergen by 12 months of age.ResultsOperating characteristics of trial decision rules were evaluated by trial simulation. The selected rules for success and futility approximately maintain type I error of 0.05 and achieved power 0.85 for a reduction in the primary outcome from 10% in the control group to 7% in the intervention group.DiscussionA detailed, prospective statistical analysis plan (SAP) is presented for this Bayesian adaptive design. The plan was written by the trial statistician and details the study design, pre-specified adaptive elements, decision thresholds, statistical methods, and the simulations used to evaluate the operating characteristics of the trial. Application of this SAP will minimise bias and supports transparent and reproducible research.Trial registrationAustralia & New Zealand Clinical Trials Registry,ACTRN12617000065392. Registered on 12 January 2017Study protocol10.1136/bmjopen-2020-042838

Funder

national health and medical research council

telethon new children's hospital research fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Reference20 articles.

1. Estcourt MJ, Campbell DE, Gold MS, Richmond P, Allen KJ, Quinn HE, Marsh JA, Peters RL, Valerio C, Dai D, et al. Whole-cell pertussis vaccination and decreased risk of ige-mediated food allergy: A nested case-control study. J Allergy Clin Immunol Pract. 2020; 8(6):2004–14.

2. Perez Chacon G, Estcourt MJ, Totterdell J, Campbell DE, Perrett KP, Marsh JA, Richmond PC, Wood N, Gold MS, Holt PG, Waddington CS, Snelling TL. OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule. BMJ Open. 2020; 10(12). https://doi.org/10.1136/bmjopen-2020-042838. http://arxiv.org/abs/https://bmjopen.bmj.com/content/10/12/e042838.full.pdf.

3. Sampson HA, Van Wijk RG, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, Dubois AE, Beyer K, Eigenmann PA, Spergel JM, et al. Standardizing double-blind, placebo-controlled oral food challenges: American academy of allergy, asthma & immunology–european academy of allergy and clinical immunology practall consensus report. J Allergy Clin Immunol. 2012; 130(6):1260–74.

4. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008; 335(1-2):79–89.

5. McAlister SM, van den Biggelaar AHJ, Thornton RB, Richmond PC. Optimising a 6-plex tetanus-diphtheria-pertussis fluorescent bead-based immunoassay. MethodsX. 2021; 8:101360. https://doi.org/10.1016/j.mex.2021.101360.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3